Stock Plans (Details Narrative) - Titan Pharmaceuticals Inc [Member] - USD ($) |
12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|
Oct. 01, 2025 |
Jan. 02, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
Jun. 30, 2025 |
Jan. 01, 2025 |
Aug. 31, 2015 |
Feb. 28, 2014 |
|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
| Number of shares agreed to issue | 90,000 | |||||||
| Stock options outstanding to purchase | 0 | 79,000 | ||||||
| Weighted average exercise price per share | $ 69.85 | |||||||
| Weighted average remaining contractual term, outstanding (years) | 7 years 1 month 6 days | |||||||
| Shares, granted or exercised | 0 | |||||||
| Shares, cancelled/expired | 11,000 | |||||||
| Conversion of stock description | At the effective time of the merger with Black Titan, the remaining outstanding options to purchase approximately 68,000 shares were assumed by Black Titan and converted into options to purchase ordinary shares of Black Titan on a one-for-one basis, with the exercise price, vesting terms and contractual life of each award remaining unchanged. | |||||||
| Shares, Assumed by Black Titan | 68,000 | |||||||
| Shares, exercisable | 0 | |||||||
| Stock-based compensation expense | $ 0 | $ 0 | ||||||
| Unrecognized compensation expense related to non-vested stock option | $ 0 | $ 0 | ||||||
| Plan 2015 [Member] | ||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
| Number of shares agreed to issue | 215,000 | 30 | ||||||
| Shares available for grant | 17,311 | |||||||
| Stock options outstanding to purchase | 9 | 79,498 | ||||||
| X | ||||||||||
- Definition Share based compensation arrangement by share based payment award options assumed in period. No definition available.
|
| X | ||||||||||
- Definition A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of cost not yet recognized for nonvested award under share-based payment arrangement. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of noncash expense for share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of shares authorized for issuance under share-based payment arrangement. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Gross number of share options (or share units) granted during the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of options outstanding, including both vested and non-vested options. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|